FOLD - Amicus Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
159,588
91,245
36,930
4,958
Cost of Revenue
19,362
14,404
6,236
833
Gross Profit
140,226
76,841
30,694
4,125
Operating Expenses
Research Development
251,683
270,902
149,310
104,793
Selling General and Administrative
165,326
127,200
88,671
71,151
Total Operating Expenses
421,471
402,318
241,574
179,186
Operating Income or Loss
-281,245
-325,477
-210,880
-175,061
Interest Expense
23,744
22,402
17,240
5,398
Total Other Income/Expenses Net
-49,187
-11,671
-225,097
-24,924
Income Before Tax
-343,096
-349,089
-449,121
-203,781
Income Tax Expense
1,644
-94
-165,119
-3,739
Income from Continuing Operations
-344,740
-348,995
-284,002
-200,042
Net Income
-344,740
-348,995
-284,002
-200,042
Net Income available to common shareholders
-344,740
-348,995
-284,002
-200,042
Reported EPS
Basic
-
-1.88
-1.85
-1.49
Diluted
-
-1.88
-1.85
-1.49
Weighted average shares outstanding
Basic
-
185,790
153,355
134,402
Diluted
-
185,790
153,355
134,402
EBITDA
-
-322,471
-428,288
-195,141